Counteracting survival functions of EBNA3C in Epstein-Barr virus (EBV)-driven lymphoproliferative diseases by combination of SAHA and bortezomib

Combination of suberoylanilide hydroxamic acid (SAHA) and bortezomib (SAHA/bortezomib) was shown to synergistically induce killing of lymphoblastoid cell lines (LCL) and Burkitt lymphoma (BL) of type III or Wp-restricted latency, both of which express EBNA3A, -3B and -3C proteins. We hypothesize tha...

Descripción completa

Detalles Bibliográficos
Autores principales: Hui, Kwai Fung, Yeung, Po Ling, Tam, Kam Pui, Chiang, Alan Kwok Shing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5982749/
https://www.ncbi.nlm.nih.gov/pubmed/29861856
http://dx.doi.org/10.18632/oncotarget.25341

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5982749/
https://www.ncbi.nlm.nih.gov/pubmed/29861856
http://dx.doi.org/10.18632/oncotarget.25341

Ejemplares similares